SCPHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.49 USD | +3.22% |
|
-1.54% | -28.39% |
| Sales 2024 * | 40.01M 3.2B | Sales 2025 * | 97.75M 7.82B | Capitalization | 162M 12.96B |
|---|---|---|---|---|---|
| Net income 2024 * | -58M -4.64B | Net income 2025 * | -26M -2.08B | EV / Sales 2024 * | 4.05 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.66 x |
| P/E ratio 2024 * |
-3.04
x | P/E ratio 2025 * |
-7.28
x | Employees | 136 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.93% |
More Fundamentals
* Assessed data
More news
Latest transcript on scPharmaceuticals Inc.
More recommendations
More press releases
| 1 day | +3.22% | ||
| 1 week | -1.54% | ||
| Current month | -10.56% | ||
| 1 month | -8.55% | ||
| 3 months | -15.60% | ||
| 6 months | -20.81% | ||
| Current year | -28.39% |
1 week
4.27
4.79
1 month
4.255.33
Current year
4.256.60
1 year
4.2512.75
3 years
3.4812.75
5 years
2.7812.75
10 years
2.4418.17
| Managers | Title | Age | Since |
|---|---|---|---|
John Tucker
CEO | Chief Executive Officer | 61 | 31/12/16 |
Rachael Nokes
DFI | Director of Finance/CFO | 49 | 31/08/14 |
John Mohr
CTO | Chief Tech/Sci/R&D Officer | - | 31/01/17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 78 | 31/12/13 | |
Klaus Veitinger
BRD | Director/Board Member | 62 | 20/11/17 |
John Tucker
CEO | Chief Executive Officer | 61 | 31/12/16 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 4.49 | +3.22% | 119,733 |
| 25/04/24 | 4.35 | -3.33% | 187,355 |
| 24/04/24 | 4.5 | -2.39% | 92,041 |
| 23/04/24 | 4.61 | +0.88% | 85,259 |
| 22/04/24 | 4.57 | +0.22% | 113,931 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Companayâs pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.
Sector
Pharmaceuticals
Calendar
07/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.49
USD
Average target price
19.5
USD
Spread / Average Target
+334.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -28.39% | 162M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- SCPH Stock
